Company Data
CNPJ
Market Cap
Number of Shares
Listing Segment
IPO Date
Key Indicators
P/E
P/VP
DY
Tag Along
Free float
Viability Seal
We use cookies that are necessary for the site to work and, with your permission, analytics and marketing cookies to improve your experience. You can accept all of them or choose what to allow.
Company Data
CNPJ
Market Cap
Number of Shares
Listing Segment
IPO Date
Key Indicators
P/E
P/VP
DY
Tag Along
Free float
Viability Seal
See what thousands of investors think and vote on the assets you consider viable
Company Data
CNPJ
12.108.897/0001-50
Market Cap
R$283M
Number of Shares
50.6M
Listing Segment
NOVO MERCADO
IPO Date
8/10/2020
Key Indicators
P/E
13.01
P/VP
0.31
DY
---
Tag Along
100.00%
Free float
33.24%
Viability Seal
Find out whether the asset is viable or a dud
Loading data
Discover whether an asset is an opportunity or a risk through our seal.
CASH3
Méliuz S.A
PETR4
Petróleo Brasileiro S.A Petrobras
ABEV3
Ambev S.A
ITUB3
Itaú Unibanco Holding S.A
The stock is undefined relative to the fair price by the Graham formula.
R$4.83
d1000 is a pharmacy chain formed by the acquisitions of Drogasmil, Farmalife, Drogaria Rosário, and Tamoio. The company operates in the Federal District, Rio de Janeiro, Goiás, Mato Grosso, and Tocantins. The brands that make up the company have been present in the market for over 40 years and together employ more than 3,600 people.
In addition, the d1000 pharmacy network serves about 2.5 million consumers per month. The company uses a multi-faceted and complementary platform that caters to all social classes of the Brazilian population. To achieve this, d1000 employs a characteristic popular model that respects and addresses the particularities of each region where it operates.
Currently, d1000 is the largest revenue-generating network of Abrafarma – Brazilian Association of Pharmacy and Drugstore Chains. Furthermore, the company is part of the Profarma Group through its product distribution platform.
Being part of the Profarma Group, d1000 has several advantages, such as: daily deliveries; use of the distributor's stock; lower working capital requirements; leveraging administrative synergies – through the Shared Services Center, among others.
Thus, the company's operations are focused on the commercialization of:
Medicines (including branded, that is, prescription drugs);
generics and OTC / MIPS;
personal hygiene products;
beauty and dermocosmetics (“HB”);
convenience products.
The history of d100 began in 2016 when Profarma Distribuidora de Produtos Farmacêuticos, a Brazilian company founded in 1961 in Rio de Janeiro, acquired the pharmacy chains Drogasmil, Farmalife, Drogaria Rosário, and Tamoio and decided to segregate the retail operations into a new company. Thus, d100 was born.
Additionally, the company went public (IPO) in 2020 on the Novo Mercado, the highest level of governance at B3. One of the company's differentiators is the campaigns conducted, such as “Diga Sim Pra Mim” and “Somar Faz a Diferença”.
Both campaigns are aimed at raising donations from customers, as well as directing them to UNICEF.
